Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
eqs_en 
0 23.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 22.03.23
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
eqs_en 
0 21.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 21.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 20.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 17.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 16.03.23
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
eqs_en 
0 16.03.23
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
eqs_en 
0 15.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 15.03.23
EQS-Adhoc: GN Store Nord A/S: Update on the agenda for GN Store Nord’s Annual General Meeting and capital raise: https://mms.businesswire.com/media/20220816005068/en/1543852/5/GN_Logo_RGB_300ppi.jpg
EQS-Adhoc: GN Store Nord A/S: Update on the agenda for GN Store Nord’s Annual General Meeting and capital raise
EQS-Adhoc: GN Store Nord A/S: Update on the agenda for GN Store Nord’s Annual General Meeting and capital raise
eqs_en 
0 15.03.23
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
eqs_en 
0 14.03.23
Geisinger and Acadia Healthcare Appoint Kelly Ankenbrand as CEO of Geisinger Behavioral Health Center Northeast: https://mms.businesswire.com/media/20230314005483/en/1737687/5/Kelly_Ankenbrand_photo.jpg
Geisinger and Acadia Healthcare Appoint Kelly Ankenbrand as CEO of Geisinger Behavioral Health Center Northeast


Geisinger and Acadia Healthcare have named Kelly Ankenbrand, M.B.A., as chief executive officer for Geisinger Behavioral Health Center Northeast, a new 96-bed inpatient behavioral health hospital

BusinessWire_EN 
0 14.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 14.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 13.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 10.03.23
LivaNova erhält 510(k)-Freigabe der US-amerikanischen FDA für Essenz-Herz-Lungen-Maschine für kardiopulmonale Bypassverfahren: https://mms.businesswire.com/media/20230309005788/de/1735168/5/Essenz_DMcDonald_Milano_2023_03_02-12.jpg
LivaNova erhält 510(k)-Freigabe der US-amerikanischen FDA für Essenz-Herz-Lungen-Maschine für kardiopulmonale Bypassverfahren


LivaNova PLC (Nasdaq: LIVN), ein marktführendes Unternehmen im Bereich medizintechnische Innovationen, gab heute bekannt, dass es die 510(k)-Freigabe von der US-amerikanischen Food and Drug

BusinessWire_DE 
0 10.03.23
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures: https://mms.businesswire.com/media/20230309005787/en/1735168/5/Essenz_DMcDonald_Milano_2023_03_02-12.jpg
LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™

BusinessWire_EN 
0 09.03.23
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
eqs_en 
0 09.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 09.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 08.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 07.03.23
Acadia Healthcare Breaks Ground on New Behavioral Health Hospital in Arizona: https://mms.businesswire.com/media/20230306005668/en/1731758/5/ACHCAgave_BH_Groundbreaking_3.6.2023.jpg
Acadia Healthcare Breaks Ground on New Behavioral Health Hospital in Arizona


Acadia Healthcare Company today held a groundbreaking ceremony marking the beginning of construction on the new hospital that the company is building to serve residents of Mesa, Arizona, and

BusinessWire_EN 
0 07.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 06.03.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 03.03.23